Regentis Biomaterials Ltd. (RGNT) Stock Forecast
RGNT analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 1 analysts
- Price target
- $10.00 average of analyst targets
- Upside to target
- +571.1% from the latest close
- Next earnings
- —
- 52-week range
- $1.28 – $9.40
RGNT analyst ratings
1 analystsNumber of analysts at each rating.
RGNT price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
RGNT earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current fiscal year (2026) | −$0.68 | −$0.68 | −$0.68 | — | — | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
RGNT revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current fiscal year (2026) | $0 | $0 | $0 | — | 1 |
| Next fiscal year (2027) | $0 | $0 | $0 | — | — |
RGNT EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
RGNT EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current fiscal year (2026) | $0.00 | $0.00 | $0.00 | $0.00 | −$0.68 | — | 0 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
What analysts expect from RGNT
1 analysts cover Regentis Biomaterials; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $10.00, 571.1% above the latest close of $1.49. Analysts expect earnings of −$0.68 per share for 2026.
Related: RGNT income statement, RGNT key metrics, RGNT chart. See the RGNT stock overview for the latest quote and news.
RGNT forecast FAQ
What is Regentis Biomaterials's price target?
The average analyst price target for Regentis Biomaterials is $10.00, 571.1% above the latest close of $1.49.
Is Regentis Biomaterials a buy, hold or sell?
Of 1 analysts covering Regentis Biomaterials, 1 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Regentis Biomaterials's EPS forecast?
Analysts forecast −$0.68 per share for 2026 (range −$0.68 to −$0.68).